REGN•benzinga•
Regeneron Pharmaceuticals Reveals Initial Results From Two Cohorts Of The Phase 1b LINKER-MM2 Trial Evaluating Linvoseltamab In Combination With Two Different Proteasome Inhibitors – Carfilzomib Or Bortezomib – In Patients With Relapsed/Refractory Multipl
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2025 by benzinga